Trifluoper<wbr/>azine-d<sub>3</sub> (hydro<wbr/>chloride)

Trifluoperazine-d3 (hydrochloride)

CAT N°: 30718
Price:

313.00 266.05

Trifluoperazine-d3 is intended for use as an internal standard for the quantification of trifluoperazine (Item No. 15068) by GC- or LC-MS. Trifluoperazine (TFP) is a phenothiazine compound with anti-adrenergic and anti-dopaminergic actions typical of antipsychotic agents.{24253} It antagonizes adrenergic receptors, with selectivity for ?1 over the ?2 subtypes (Kis = 24, 653, 163, and 391 nM for ?1A, ?2A, ?2B, and ?2C, respectively). TFP binds with much higher affinity to the dopamine D2-like receptor (Kd = 0.96 nM) compared to the dopamine D4-like and the serotonin 5-HT2A receptors (Kds = 44 and 135 nM, respectively).{24252} Furthermore, TFP antagonizes calmodulin (CaM) and alters the calcium-binding properties of calsequestrin (CSQ).{23719,24254} TFP has been shown to activate type-2 ryanodine receptors independently of its CaM and CSQ activity.{24254}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 10-[3-(4-methyl-d3-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine, dihydrochloride
  • Correlated keywords
    • 81498-90-0 GCMS LCMS Deuturium deuterated antiadrenergic antidopaminergic anti psychotic ? 1 2 1A 2A 2B 2C 5HT D 2 4 trifluo perazine
  • Product Overview:
    Trifluoperazine-d3 is intended for use as an internal standard for the quantification of trifluoperazine (Item No. 15068) by GC- or LC-MS. Trifluoperazine (TFP) is a phenothiazine compound with anti-adrenergic and anti-dopaminergic actions typical of antipsychotic agents.{24253} It antagonizes adrenergic receptors, with selectivity for ?1 over the ?2 subtypes (Kis = 24, 653, 163, and 391 nM for ?1A, ?2A, ?2B, and ?2C, respectively). TFP binds with much higher affinity to the dopamine D2-like receptor (Kd = 0.96 nM) compared to the dopamine D4-like and the serotonin 5-HT2A receptors (Kds = 44 and 135 nM, respectively).{24252} Furthermore, TFP antagonizes calmodulin (CaM) and alters the calcium-binding properties of calsequestrin (CSQ).{23719,24254} TFP has been shown to activate type-2 ryanodine receptors independently of its CaM and CSQ activity.{24254}

We also advise you